Kadmon Holdings Inc.

07/16/2021 | Press release | Distributed by Public on 07/16/2021 12:22

U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)